Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Insulin
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Sponsor : CalRx Biosimilar Insulin Initiative
Deal Size : $50.0 million
Deal Type : Partnership
California Selects Civica Rx as Its Insulin Manufacturing Partner
Details : Under the agreement, Californians with diabetes will have access to Civica’s low-cost insulins via the CalRx Biosimilar Insulin Initiative. Civica will produce three insulins, glargine, lispro and aspart, available both in vials and prefilled pens unde...
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Undisclosed
March 18, 2023
Lead Product(s) : Insulin
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Sponsor : CalRx Biosimilar Insulin Initiative
Deal Size : $50.0 million
Deal Type : Partnership
Lead Product(s) : Abiraterone Acetate,Prednisone
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CivicaScript Announces Launch of its First Product, Creating Significant Patient Savings
Details : Abiraterone acetate 250 mg is indicated in combination with prednisone for the treatment of people with metastatic castration-resistant prostate cancer (CRPC) and those with metastatic high-risk castration-sensitive prostate cancer (CSPC).
Product Name : Abiraterone Acetate-Generic
Product Type : Hormone
Upfront Cash : Inapplicable
March 08, 2022
Lead Product(s) : Abiraterone Acetate,Prednisone
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Insulin Glargine
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : GeneSys Biologics
Deal Size : Undisclosed
Deal Type : Financing
Civica Takes First Foray Into Biosimilars With GeneSys Insulins Partnership
Details : Civica will produce three insulins – glargine, lispro and aspart (biologics corresponding to, and interchangeable with, Lantus, Humalog and Novolog respectively) – each of which will be available both in vials and prefilled pens.
Product Name : Insulin Glargine-Generic
Product Type : Peptide
Upfront Cash : Undisclosed
March 03, 2022
Lead Product(s) : Insulin Glargine
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : GeneSys Biologics
Deal Size : Undisclosed
Deal Type : Financing